Developing a treatment to protect healthcare workers from Marburg virus outbreaks
Official title: Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
Funded at Abvacc, INC. · NIH-11077219 · Data updated 2026-11-12
This study is working on a new treatment to help protect healthcare workers and first responders from the Marburg virus, which can be very dangerous, by using special antibodies that can keep them safe during outbreaks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | May 12, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $914,818 |
| NIH project number | 5R44AI177045-03 |
| Project ID | NIH-11077219 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are healthcare workers and first responders who are at high risk of exposure to the Marburg virus during outbreaks.
✕Less likely to help
Patients who are not involved in healthcare or emergency response roles may not receive direct benefits from this research.
What this research studies
This research focuses on creating a prophylactic immunotherapy to protect healthcare workers and first responders from Marburg virus disease (MVD), which can cause severe viral hemorrhagic fever with high mortality rates. The approach involves developing highly potent monoclonal antibodies that can be administered in low doses while ensuring long-lasting protection. By targeting the immune response, the goal is to provide a safeguard for those on the front lines during outbreaks, thereby enhancing their safety and the overall effectiveness of outbreak control efforts.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of Marburg virus infection among healthcare workers, ultimately saving lives and maintaining healthcare system stability during outbreaks.
How similar studies have gone: Previous research on prophylactic treatments for Ebola virus has shown promise, indicating that similar approaches for Marburg virus may also be effective.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.